Julie Lin

Company: Travere Therapeutics, Inc.

Job title: Senior Vice President, Clinical Development & Clinical Pharmacology

Seminars:

11:30 AM Proteinuria: A Key Endpoint in Rare Glomerular Diseases 11:30 am

In recent years, proteinuria has become regulatory approvable endpoint for new therapeutics for rare glomerular diseases and considerations for drug developers include: Considerations of measuring urinary albumin vs. total protein Timed 24-hour proteinuria or albuminuria excretion vs. spot urinary protein-to-creatine ratio Implications of varying recommendations in KDIGO and other nephrology practice guidelinesRead more

day: Conference Day 1